Bicara Therapeutics Stock (NASDAQ:BCAX)

Ownership Financials Chart

Previous Close

$10.15

52W Range

$8.91 - $28.09

50D Avg

$12.84

200D Avg

$17.47

Market Cap

$587.22M

Avg Vol (3M)

$466.73K

Beta

-1.41

Div Yield

-

BCAX Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

-

Website

BCAX Performance

BCAX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-82.39M	$-39.89M	$-37.66M
Net Income	$-68.00M	$-51.98M	$-37.84M
EBITDA	$-82.39M	$-51.96M	$-37.72M
Basic EPS	$-0.40	$-1.00	$-0.73
Diluted EPS	$-0.40	$-1.00	$-0.73

Fiscal year ends in Dec 24 | Currency in USD